Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2001

View Archived Issues

NIH technology available for licensing: antiprogestins with partial agonist activity

Alizyme: clinical and preclinical development program update

Update of Pozen's clinical drug candidates for migraine

ProstaRex shows broad T-cell response in preclinical prostate cancer studies

AeroGen reports product update

Boehringer Ingelheim prepares large international study for prevention of cardiovascular disease

OSI begins first in series of OSI-774 trials in combination with anticancer agents

Microsphere formulation of KNI-272 tested in HIV-infected patients

Alliance plans to continue development of Oxygent

Cumulative neuromuscular toxicity is dose-limiting for LU-79553

Positive results reported from phase III trial of Novavax's Estrasorb; NDA in preparation

Millennium gains rights to PDL's antibody humanization patents

Controlled trial examines efficacy of embryonic dopamine neuron transplantation in PD

Nastech's nasal triptan enters phase I for migraine pain

Gastrointestinal and colonic prokinetic effects of prucalopride confirmed in constipated patients

Morphochem/Sosei collaboration will optimize anticancer telomerase inhibitor

Tibotec and Virco merger complete

Company Profile: Speedel

SB-273005, an orally active vitronectin receptor antagonist with disease-modifying properties

Shire seeks E.U. approval of Foznol

New doses of Kadian approved in U.S.

Patient enrollment complete in pivotal phase III trial of Xcytrin

Small-molecule inhibitors of cell adhesion in the Boehringer Ingelheim pipeline

Oral prodrugs of immunosuppressive/antiallergic compounds prepared at Shionogi

Shionogi identifies new series inhibiting sPLA2

AHP scientists claim new bicyclic vitronectin antagonists and use in osteoporosis

GlycoTech presents new sialyl-Lewis(a) and sialyl-Lewis(x) analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...